Summary:
The ATLAS Research Studies are evaluating an investigational drug: an inject able, long-acting form of aripiprazole. Approved for use in oral and short-acting inject able forms to manage Bipolar I Disorder, researchers are looking to see whether an investigational once-monthly injection of aripiprazole is a safe and effective option for long-term episode management and prevention.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Have been diagnosed with Bipolar I Disorder
•
Be currently in a mixed or manic cycle
•
Have taken at least one mood stabilizing medication to treat bipolar disorder in the past
•
Have the desire to try a once a month injection for the treatment of your bipolar disorder
•
Additional criteria will be assessed by the study doctor.
Qualified Participants May Receive:
All study-related medications, office visits and examinations will be provided to you at no cost. Your current antidepressant or one that the study doctor prescribes to you will also be provided at no cost while you are in the study. As well as monetary compensation for you time and travel at each study visit